Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

Quick Access

Favorites
Most Used

All Specialties

OpiCalc Logo
Clinical CalculatorsDrugsGuidelines
SpecsDrugsGuides
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub
Beta-2 Agonist Bronchodilator/Prescription

PROAIR RESPICLICK

PROAIR RESPICLICK

Clinical safety rating

caution

Comprehensive clinical and safety monograph for PROAIR RESPICLICK (PROAIR RESPICLICK).


Mechanism of Action

Selective beta-2 adrenergic receptor agonist; binds to beta-2 receptors on bronchial smooth muscle, activating adenylate cyclase and increasing intracellular cyclic AMP, leading to bronchodilation.

What the body does with it

MetabolismPrimarily metabolized by catechol-O-methyltransferase (COMT) and sulfatase enzymes; minor hepatic metabolism via CYP450 enzymes.
ExcretionPrimarily renal (60–70% as unchanged drug and metabolites, mainly as 4'-O-sulfate ester); biliary/fecal excretion accounts for <20%.
Half-lifeTerminal elimination half-life is 3–4 hours for inhaled albuterol; systemic half-life after inhalation is approximately 3.8 hours, supporting q4-6h dosing.
Protein bindingApproximately 50–65% bound to plasma proteins (primarily albumin).
Volume of Distribution1.5–2.5 L/kg (large Vd indicates extensive extravascular distribution, including lung tissue).
BioavailabilityInhalation: 10–20% (systemic absorption from lungs and GI tract following swallowed fraction).
Onset of Action1–3 minutes via inhalation; peak bronchodilation within 15–30 minutes.
Duration of Action4–6 hours (dose-dependent); may shorten with prolonged use due to receptor downregulation.
Molecular Weight239.31

Classification & Brands

Dosing & administration

Two inhalations (180 mcg total) orally inhaled every 4 to 6 hours as needed for bronchospasm; for prevention of exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.

Dosage formPOWDER, METERED
Renal impairmentNo dosage adjustment required for renal impairment; pharmacokinetics not significantly altered.
Liver impairmentNo specific dosage adjustment recommended based on Child-Pugh classification; pharmacokinetics not studied in hepatic impairment.
Pediatric useChildren 4 to 11 years: 2 inhalations (180 mcg total) orally inhaled every 4 to 6 hours as needed; for exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.
Geriatric useNo specific dosage adjustment required; use caution due to potential for increased sensitivity to sympathomimetic effects; monitor for adverse effects such as tremor, tachycardia, or elevated blood pressure.

Use during pregnancy

1st trimesterAlbuterol is generally considered safe in pregnancy; studies have not shown an increased risk of congenital anomalies. However, use only if clearly needed.
2nd trimesterNo known harm; may be used for bronchospasm management. Monitor for maternal tachycardia and hyperglycemia.
3rd trimesterMay cause transient fetal tachycardia and hyperglycemia if used near term. Use lowest effective dose.

Clinical note

Comprehensive clinical and safety monograph for PROAIR RESPICLICK (PROAIR RESPICLICK).

Placental transferAlbuterol crosses the placenta; detectable concentrations in fetal blood are approximately 30-50% of maternal concentrations.
BreastfeedingAlbuterol is excreted into breast milk in small amounts. It is unlikely to cause adverse effects in the infant. However, monitor for signs of beta-adrenergic stimulation (e.g., tachycardia, irritability).
Lactation RatingL2 (Safer)
Teratogenic RiskPregnancy Category C. In animal studies, albuterol administered subcutaneously at doses 0.5-50 times the maximum recommended human inhalation dose (MRHID) caused cleft palate, delayed ossification, and decreased fetal weight. No adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies risk. First trimester: Risk cannot be ruled out. Second and third trimesters: Risk of maternal tachycardia, hypoglycemia, and hypokalemia; preterm labor inhibition may occur; avoid use during labor due to risk of transient fetal hypoglycemia.
Fetal MonitoringMonitor maternal heart rate, blood pressure, serum potassium, and blood glucose. In pregnancy, monitor fetal heart rate and uterine activity during acute exacerbations. Consider fetal ultrasound to rule out congenital anomalies if exposure occurs during first trimester.
Fertility EffectsNo formal fertility studies in humans. In animal studies, albuterol caused decreased fertility and reduced conception rates in rats at high doses (50 times MRHID). Clinical significance unknown.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to albuterol or any componentCardiac arrhythmias associated with tachycardia (e.g., atrial fibrillation with rapid ventricular response)

Clinical Precautions

PrecautionsParadoxical bronchospasm may occur, which can be life-threatening, Cardiovascular effects: increased heart rate, blood pressure, or ECG changes; use caution in patients with cardiovascular disorders, Fatalities reported with excessive use, Immediate hypersensitivity reactions (urticaria, angioedema, rash), Do not exceed recommended dose; excessive use may lead to death, Hypokalemia and hyperglycemia may occur, especially with high doses
Food/DietaryNo specific food interactions. Avoid xanthine-containing foods (caffeine) if experiencing excessive stimulation; however, no direct interaction with albuterol.

Clinical Tips & Counseling

Clinical PearlsPROAIR RESPICLICK is a breath-actuated inhaler containing albuterol sulfate, a short-acting beta-2 agonist (SABA). It does not require coordination between actuation and inhalation, making it suitable for patients with difficulty using traditional MDIs. Priming is needed after 7 days of non-use or if dropped; shake well before each use. Monitor for paradoxical bronchospasm and excessive use indicating poorly controlled asthma.
Patient AdviceUse exactly as prescribed; do not increase dose or frequency without consulting your doctor. · Prime the inhaler with 4 test sprays into the air if not used for 7 days or after cleaning or dropping. · Shake the inhaler well before each use. · Breathe out fully, place mouthpiece in mouth, seal lips, and inhale deeply and forcefully to trigger dose delivery. · Hold breath for 10 seconds then exhale slowly. · Rinse mouth with water after each use to prevent oral thrush or throat irritation. · Seek emergency help if symptoms worsen or if relief lasts less than 3 hours. · Store at room temperature away from moisture and heat; do not puncture or incinerate.

PROAIR RESPICLICK Interactions

Loading safety data…

This overview is compiled from peer-reviewed clinical sources and FDA labeling. It's here to support — not replace — clinical judgment. Always verify dosing against your institution's current protocols before prescribing.

On this page

Mechanism of ActionDosing & administrationUse during pregnancyWarnings & precautionsDrug interactions

Compare with

NOXIVENTPROAIR DIGIHALERPROAIR HFA

External sources

DailyMed (NIH) PubMed OpenFDA